The information in this section is intended for visitors outside the United States.
Our esteemed Board of Directors provide the leadership and guidance necessary to execute our mission and realize our vision.
Dr. Martin joined Gilead Sciences in 1990 and was appointed Executive Chairman in March 2016. He served as Chairman and Chief Executive Officer from June 2008 through March 2016 and President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation.
Dr. Martin previously served as President of the International Society for Antiviral Research, Chairman of the Board of Directors of BayBio and Chairman of the Board of Directors of the California Healthcare Institute (CHI). He served on the National Institute of Allergy & Infectious Diseases Council, the Board of Directors of the Biotechnology Industry Organization, the Board of Directors for CHI, the Board of Trustees of the University of Chicago, the Board of Trustees of Golden Gate University and the External Scientific Advisory Board of the University of California School of Global Health. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administration's Advisory Committee on HIV and STD Prevention and Treatment and was a member of the Presidential Advisory Council on HIV/AIDS.
Dr. Martin holds a PhD in organic chemistry from the University of Chicago, an MBA from Golden Gate University and a bachelor’s of science degree in chemical engineering from Purdue University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies.
John F. Cogan, PhD joined Gilead’s Board of Directors in July 2005 and was appointed Lead Independent Director in May 2013. Dr. Cogan is currently the Leonard and Shirley Ely Senior Fellow at the Hoover Institution at Stanford University, where he has had a continuing appointment since 1980. Dr. Cogan’s current research is focused on U.S. budget and fiscal policy, health care and social security. Dr. Cogan has held a number of positions in the U.S. government, including Assistant Secretary for Policy in the U.S. Department of Labor and Associate Director and Deputy Director in the U.S. Office of Management and Budget. Dr. Cogan is a trustee of the Charles Schwab Family of Funds.
Kelly A. Kramer joined Gilead’s Board of Directors in August 2016. Ms. Kramer is currently Executive Vice President and Chief Financial Officer of Cisco Systems, Inc. She previously served as Vice President and Chief Financial Officer of GE Healthcare Systems and Chief Financial Officer of GE Healthcare Biosciences. Ms. Kramer has also worked in GE’s Corporate Headquarters, Transportation Systems and Aerospace divisions. She is a member of the board of the Silicon Valley Chapter of City Year, a non-profit organization that provides educational support for at-risk students in poor communities.
Kevin E. Lofton joined Gilead’s Board in July 2009. He is currently the Chief Executive Officer of Catholic Health Initiatives. Headquartered in Denver, the healthcare system has revenues of over $16 billion and operates the full continuum of services from hospitals to home health agencies throughout the nation. He previously served as Chief Executive Officer of two university hospitals, the UAB Hospital and Howard University Hospital. In 2007, Mr. Lofton served as Chairman of the Board of the American Hospital Association, the nation’s largest hospital trade association. In May 2016 he received an honorary Doctor of Humanities in Medicine degree from the Baylor College of Medicine. In June 2014 The Healthcare Financial Management Association awarded the Richard L. Clarke Board of Directors Award to Mr. Lofton, in recognition of his extensive and far reaching work in the area of health care disparities and creating healthier communities. Mr. Lofton also serves on the Board of Directors of the Rite Aid Corporation.
John W. Madigan joined our Board in 2005. He is the retired Chairman and Chief Executive Officer of Tribune Company, a director and former Chairman of the Robert R. McCormick Foundation. Mr. Madigan is also a former member of the Defense Business Board of the Department of Defense, a former advisor to Madison Dearborn Partners and a director and former Chairman of The Chicago Council on Global Affairs. He previously served as a director of AT&T Wireless, Boise Cascade Holdings, L.L.C and Morgan Stanley. He serves as a trustee of Northwestern University and Rush University Medical Center. Mr. Madigan is a member and former Chairman of The Commercial Club of Chicago and a director of New Schools for Chicago.
Dr. Milligan joined Gilead Sciences in 1990 and was appointed Chief Executive Officer in March 2016. He was appointed President in 2008, and from 2007 to 2016 served in the role of Chief Operating Officer as well. He previously held multiple leadership roles within Gilead, including the position of Chief Financial Officer from 2002 to 2007.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology industry CFO in the United States by Institutional Investor magazine in 2006, 2007 and 2008. He is a member of the boards of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization, and Pacific Biosciences of California, Inc. He is also a Trustee of Ohio Wesleyan University.
Dr. Milligan received his BA from Ohio Wesleyan University, his PhD in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
Nicholas G. Moore joined Gilead’s Board of Directors in March 2004. Mr. Moore is the retired global Chairman of PricewaterhouseCoopers LLP, a professional services firm formed in July 1998 by the merger of Coopers & Lybrand and Price Waterhouse. Prior to the merger, Mr. Moore was elected Chairman and Chief Executive Officer of Coopers & Lybrand (U.S.) in 1994 and Coopers & Lybrand International in 1997. Mr. Moore is a director of Bechtel Group, Inc. and previously served as lead independent director at NetApp and director and Chairman of the audit committee at Wells Fargo. He has also served as Chairman of the Board of Trustees of St. Mary’s College of California. Mr. Moore is an inactive member of the American Institute of Certified Public Accountants, the California Bar Association, and the California and New York Society of Certified Public Accountants.
Dr. Shultz served on our Board from January 1996 to January 2006. Dr. Shultz currently serves as Distinguished Fellow at the Hoover Institution. Dr. Shultz served as U.S. Secretary of State from 1982 to 1989 and earlier served as Secretary of Labor, Director of the Office of Management and Budget and Secretary of the Treasury. Previously, he served as Dean of the Graduate School of Business at the University of Chicago and as President of Bechtel Group, Inc. In 1989, Dr. Shultz was awarded the Presidential Medal of Freedom.
Dr. Whitley joined Gilead's Board of Directors in 2008. He is a Distinguished Professor, Loeb Scholar Chair in Pediatrics, and Professor of Microbiology, Medicine and Neurosurgery at the University of Alabama at Birmingham. He is the Co-Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Director for Drug Discovery and Development and Senior Leader, Comprehensive Cancer Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Founder and Co-Director, Alabama Drug Discovery Alliance. Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, and directs a Center for drug discovery in the arena of emerging infections. He is a past President of the International Society of Antiviral Research and the Infectious Diseases Society of America, and currently chairs both the NIAID Recombinant DNA Advisory Council and the NIAID HIV Vaccine Data Safety and Management Board. He is an elected member of the American Society of Clinical Investigation and the Association of American Physicians.
Gayle Edlund Wilson joined Gilead’s Board of Directors in October 2001. Mrs. Wilson served as California’s First Lady from 1991 to 1999. Mrs. Wilson is a member of the board of directors of the Ralph M. Parsons Foundation, a non-profit organization that provides grants for higher education, social impact, civic, cultural issues and health issues. She is also the Chair Emeritus of the Advisory Board of the California State Summer School for Math and Science, and a member of the board of trustees of the California Institute of Technology.
Mr. Wold-Olsen joined Gilead’s Board of Directors in January 2010 after serving as the Chair of the company’s Health Policy Advisory Board since 2007. From 2005 to 2006, Mr. Wold-Olsen served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a leading global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck & Co.,Inc. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S. He also serves as a director of Novo A/S. Mr. Wold-Olsen is the Chair of the Board of the Medicines for Malaria Venture (MMV), a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria.
Mr. Wold-Olsen previously served as a director of PharmaNet Development Group, Inc., Royal Duch Numico, Exicon A/S and H. Lundbeck A/S.
In his more than 30-year career at Merck, Mr. Wold-Olsen held various leadership positions within the company with responsibility for 15,000 employees in more than 100 markets in Europe, Eastern Europe, Middle East/Africa, India, Latin America and Canada. Mr. Wold-Olsen played an integral part in Merck’s significant growth in the European market, led a reassessment of Merck’s strategy in India after the company’s 20-year absence in the country, provided leadership to the company’s corporate responsibility initiatives as member of the Merck Company Foundation Oversight Committee, and helped direct the company’s HIV/AIDS initiatives in emerging markets and the developing world. A Principal Board member of the Accelerating Access Initiative (AAI), Mr. Wold-Olsen helped spearhead Merck’s involvement with the coalition, which was responsible for supplying HIV treatment to more than 700,000 patients in the developing world from 2000 to 2005. In addition to AAI, Mr. Wold-Olsen led several of Merck’s HIV/AIDS access initiatives, including a partnership among the Merck Company Foundation, Bill & Melinda Gates Foundation and the Government of Botswana to address HIV in the country, as well as a partnership with the Government of Romania aimed at eradicating pediatric AIDS and providing universal access to antiretrovirals.
Mr. Wold-Olsen is recognized worldwide for his leadership in pharmaceutical marketing and policy issues, and has written articles on the topics for publications including Wall Street Journal Europe, Eurohealth and SCRIP.
He is a current Chair of the Board of Medicines for Malaria Venture, Chairman of the Board of a top 20 listed Global Danish based Company, active with several biotech Boards and a past Chair and past member of the Europe Committee of Pharmaceutical Research and Manufacturers of America (PhRMA).
Mr. Wold-Olsen received MBAs in Economics/Administration from the Norwegian School of Management and in Management/Marketing from the University of Wisconsin.